CD8A and B-cell acute lymphoblastic leukemia: Finally, in a clinical trial (NCT01865617) which investigated the effectiveness of CD19-redirected CAR-T cells against B-cell acute lymphoblastic leukemia (B-ALL), Turtle et al. noted a CD8+ T-cell-mediated immune response against adoptively transferred cells expressing the synthetic receptor.